Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges
Endocrine Reviews · 30.10.2026
DOI: 10.1210/endrev/bnag040 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 30.10.2026. Verfasst von Cristian A Carvajal und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. Die Arbeit nennt 118 Literaturangaben. Gefördert von: ANID-FONDECYT, ICM-ANID, ANID-DOCTORADO NACIONAL.
Abstract (Originalsprache)
Hypertension affects over 1.3 billion people worldwide and is the leading modifiable cause of cardiovascular morbidity and mortality. Approximately one-third of individuals with hypertension exhibit a low-renin phenotype, a clinically heterogeneous subgroup in which the underlying etiology remains uncharacterized in most cases. Among its mechanistic contributors, non-classic apparent mineralocorticoid excess (NC-AME) represents a prevalent and under recognized cause of cortisol-mediated mineralocorticoid receptor over activation that has, to date, lacked a formal clinical definition, standardized diagnostic criteria, or evidence-based therapeutic framework. This review addresses that gap. NC-AME is formally defined as a syndrome of partial 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2) insufficiency occurring in the absence of biallelic human HSD11B2 variants, biochemically characterized by an elevated cortisol-to-cortisone (F/E) ratio and low cortisone concentration, and typically associated with low plasma renin, normal-to-low aldosterone, and elevated blood pressure. The review consolidates evidence across 3 mechanistic domains, genetic and epigenetic dysregulation of HSD11B2 gene, endogenous and exogenous enzyme inhibition, and patient-specific alterations (ie, age, sex, renal function), and proposes a structured LC-MS/MS-based diagnostic algorithm, and a resource-adapted diagnostic approach. Mineralocorticoid receptor antagonists are endorsed as mechanism-directed first-line therapy, with blood pressure and renin normalization as co-primary treatment targets. Acquired and reversible causes are classified separately to guide clinical management. A research agenda is advanced to drive threshold standardization, multicenter validation, and integration of NC-AME into hypertension guidelines across endocrinology, cardiology, and nephrology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Centro Traslacional de Endocrinología UC (CETREN), Santiago, Chile.
- Millennium Institute on Immunology and Immunotherapy, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.
- Facultad de Ingeniería, Universidad Finis Terrae, Santiago, Chile.
- Center for Adrenal Disorders, Division of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Harvard Medical School, Boston, USA.
ORCID-Profile: Cristian A Carvajal, Alejandra Tapia-Castillo, Thomas Uslar, Anand Vaidya, Jorge A Pérez, René Baudrand, Carlos E Fardella
Förderung
- ANID-FONDECYT
- ICM-ANID
- ANID-DOCTORADO NACIONAL
- ANILLO ACT
- SOCHED
- AVANZA-UC
- CETREN-UC
Zitieren
APA
Carvajal, C. A., Tapia-Castillo, A., Uslar, T., Vaidya, A., Pérez, J. A., Baudrand, R., & Fardella, C. E. (2026). Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges. Endocrine Reviews. https://doi.org/10.1210/endrev/bnag040
Vancouver
Carvajal CA, Tapia-Castillo A, Uslar T, Vaidya A, Pérez JA, Baudrand R, et al. Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges. Endocrine Reviews. 2026. doi:10.1210/endrev/bnag040
BibTeX
@article{Carvajal2026,
author = {Carvajal, Cristian A and Tapia-Castillo, Alejandra and Uslar, Thomas and Vaidya, Anand and Pérez, Jorge A and Baudrand, René and Fardella, Carlos E},
title = {Non-classic apparent mineralocorticoid excess syndrome: current evidence and future challenges},
journal = {Endocrine Reviews},
year = {2026},
doi = {10.1210/endrev/bnag040}
}
EUVIMED